Korea’s Green Cross Receives U.S. FDA Orphan Drug Status For Elaprase Biobetter
This article was originally published in PharmAsia News
Executive Summary
South Korea’s Green Cross wins U.S. FDA orphan drug designation for Hunterase, its biobetter of Shire’s Elaprase to treat Hunter syndrome.